H.R. 3437 · 117th Congress
LOANS for Biomedical Research Act
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 117th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
D
RushSponsor19 cosponsors · 17 D, 2 R
D
Bishop
JC
D
Cooper
SC
D
Cohen
AC
D
Carson
DD
D
Davis
BF
R
Fitzpatrick
RG
D
Grijalva
ML
D
Levin
TS
D
Sewell
BS
D
Schneider
BT
D
Thompson
JA
D
Auchincloss
JG
D
Gottheimer
JR
R
Rutherford
TO
D
O’Halleran
DR
D
Ross
JH
D
Huffman
MD
D
Doyle
GK
D
Butterfield11 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
Long-term Opportunities for Advancing New Studies for Biomedical Research Act or the LOANS for Biomedical Research Act
What it does: CRS summary · Introduced in House · May 20, 2021
Long-term Opportunities for Advancing New Studies for Biomedical Research Act or the LOANS for Biomedical Research Act
This bill requires the Department of Health and Human Services (HHS), in consultation with the Department of the Treasury, to establish the Biobonds Program to support loans for clinical trials for eligible drugs and medical devices.
Specifically, Treasury must contract with institutions to act as fiscal agents to carry out the program. Fiscal agents must (1) purchase loans made to borrowers engaged in eligible biomedical research activities, and (2) sell bonds comprised of such loans. HHS shall guarantee a portion of the bond payments.
An eligible borrower under this program is one conducting (or seeking to conduct) research related to a drug or device that is (1) intended to meet an unmet medical need; and (2) under investigation in certain types of controlled clinical trials, including a trial to investigate the safety and effectiveness of the drug or device.
HHS must issue rules relating to various aspects of the program, including rules concerning (1) which loans should be prioritized for purchase, (2) the terms and conditions of the loans, and (3) the size of each bond issuance. Treasury must issue rules relating to the program's underwriting practices and compensation for the fiscal agents.
The Government Accountability Office must periodically report to Congress on the program, including an analysis of the risk to the government in guaranteeing the bonds.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: LOANS for Biomedical Research Act
Also known as: Long-term Opportunities for Advancing New Studies for Biomedical Research Act
Latest action (May 21, 2021): Referred to the Subcommittee on Health.
Policy area: Health · Origin: House · Introduced: May 20, 2021
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.